CBD Motor Thresholds: Why a Pre–Post Change Is Not a Placebo-Controlled Effect
A measurement that changes after CBD is not necessarily a measurement changed by CBD. A small crossover trial illustrates why baseline differences, treatment-by-time comparisons and exploratory analyses matter when interpreting brain-stimulation findings.
The study compared CBD with a matched placebo
Healthy men received a single 1,500-mg oral dose of highly purified CBD or placebo in a randomized, double-blind crossover design. Fifteen participants completed the full neurophysiological protocol. Researchers combined transcranial magnetic stimulation with muscle electrical recordings and EEG, testing before dosing and at one, four and six hours.
These measurements examined motor thresholds, inhibition and electrical responses to stimulation. They were not tests of seizure reduction in patients, driving ability or relief of a neurological disease. CBD concentrations were measured in serum; the electrical recordings were separate physiological endpoints.
The baseline difference changes the interpretation
Resting motor threshold differed between the two conditions before treatment. Some later measurements also changed within the CBD session, including active motor threshold at selected times. However, the relevant analyses did not establish a significant treatment-by-time interaction for these threshold findings.
That distinction is practical. Showing a statistically significant change in one session and no significant change in the other does not, by itself, show that the changes differed significantly from each other. A crossover design helps control stable individual differences, but it does not eliminate every day-to-day baseline fluctuation.
Exploratory electrical signals were not a broad effect
The primary analyses were largely null for widespread cortical responses. A secondary longitudinal model identified a localized, transient beta-band finding. Other condition-level or qualitative signals lacked consistent time-specific support.
The paper itself urges caution about the exploratory findings and the absence of corroboration across its principal inhibition and EEG measures. It would be misleading to turn one secondary signal into proof of a general CBD mechanism while omitting the main null pattern.
Timing and population still limit the result
Some participants had their highest observed serum concentration at the final six-hour measurement. With no later sampling, the investigators could not establish that every person’s true peak had been captured. The small, healthy, male-only sample also limits extension to women, patients and repeated treatment.
When assessing a claim based on this trial, ask whether it rests on a direct placebo comparison, a within-session change or a secondary model. Each can be informative, but they support different levels of causal confidence. The experiment does not establish either a universal therapeutic mechanism or a lack of clinical benefit in every disease.
Related analysis: Adult Epilepsy CBD Outcomes: Treatment Retention and Confounding Matter.
Primary research
Viviana Santoro and colleagues. Investigating Neuropharmacological Features of the Cortical Activity of Cannabidiol GWP42003 P—A Phase 1 Clinical Trial. Brain Sciences (2026). DOI: 10.3390/brainsci16090957.
